[SCHEDULE 13D/A] YS Biopharma Co., Ltd. Warrants SEC Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

LakeShore Biopharma Co., Ltd.

(Name of Issuer)

Ordinary Shares, par value $0.0002 per share

(Title of Class of Securities)

G9845F208

(CUSIP Number)

Fung Ching Wong
Floor 4, Willow House, Cricket Square, P O Box 2804
Grand Cayman, E9, KY1-1112
1 5603646852

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/11/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. G9845F208

1

Name of reporting person

Fung Ching Wong

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CHINA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,836,010.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,836,010.00

11

Aggregate amount beneficially owned by each reporting person

9,836,010.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

23.9 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Notes in relation to Items 8, 10 and 11: This reflects the 10-for-1 share consolidation effective October 1, 2024 (the "Share Consolidation"), whereby the 98,360,094 ordinary shares, par value $0.00002 per share of the Issuer (as defined below) reported in the original Schedule 13D were consolidated into 9,836,010 Ordinary Shares (as defined below). Ms. Fung Ching Wong ("Ms. Wong") currently exercises voting and dispositive control over the Ordinary Shares registered in the names of Apex Prospect Limited ("Apex"). Apex and Ms. Wong may each be deemed to have shared voting and dispositive power over all of the shares. Notes in relation to Item 13: This percentage is calculated based on 41,212,693 Ordinary Shares issued and outstanding as of July 11, 2025, which is provided by the Issuer to the Reporting Persons (as defined below). The increase in the total number of issued shares is a result of a private placement financing announced by the Issuer on July 8, 2025.

SCHEDULE 13D

CUSIP No. G9845F208

1

Name of reporting person

Apex Prospect Limited

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,836,010.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,836,010.00

11

Aggregate amount beneficially owned by each reporting person

9,836,010.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

23.9 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

Notes in relation to Items 8, 10 and 11: This reflects the 10-for-1 Share Consolidation effective October 1, 2024, whereby the 98,360,094 ordinary shares, par value $0.00002 per share of the Issuer reported in the original Schedule 13D were consolidated into 9,836,010 Ordinary Shares. Ms. Wong currently exercises voting and dispositive control over the Ordinary Shares registered in the names of Apex. Apex and Ms. Wong may each be deemed to have shared voting and dispositive power over all of the shares. Notes in relation to Item 13: This percentage is calculated based on 41,212,693 Ordinary Shares issued and outstanding as of July 11, 2025, which is provided by the Issuer to the Reporting Persons (as defined below). The increase in the total number of issued shares is a result of a private placement financing announced by the Issuer on July 8, 2025.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares, par value $0.0002 per share
(b)	Name of Issuer: LakeShore Biopharma Co., Ltd.
(c)	Address of Issuer's Principal Executive Offices: Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, CHINA , 102629.
Item 1 Comment: This Amendment No. 1 ("Amendment No. 1") amends and supplements the Schedule 13D originally filed with the Securities and Exchange Commission on February 14, 2024 (the "Original Schedule 13D"), by Fung Ching Wong and Apex Prospect Limited (the "Reporting Persons"), with respect to the ordinary shares of LakeShore Biopharma Co., Ltd (formerly known as YS Biopharma Co., Ltd.) (the "Issuer"). Capitalized terms used herein without definition shall have the meanings set forth in the Original Schedule 13D. Except as specifically amended and supplemented by this Amendment No. 1, the Original Schedule 13D remains in full force and effect.
Item 4.	Purpose of Transaction
	Item 4 of the Original Schedule 13D is hereby amended to add the following information: This Amendment No. 1 is being filed to report a material decrease in the Reporting Persons' percentage of beneficial ownership of the Issuer's Ordinary Shares. This decrease resulted solely from an increase in the total number of the Issuer's issued Ordinary Shares following a private placement transaction announced by the Issuer on July 8, 2025. The Reporting Persons have not sold or otherwise disposed of any of the Ordinary Shares they beneficially own.
Item 5.	Interest in Securities of the Issuer
(a)	The responses of the Reporting Persons to Rows (7) through (13) of the cover pages of this Amendment No. 1 are incorporated herein by reference. As of July 11, 2025, the Reporting Persons may be deemed to be the beneficial owners of an aggregate of 9,836,010 Ordinary Shares, which represents approximately 23.9% of the Issuer's issued and outstanding Ordinary Shares. The number of Ordinary Shares reported as beneficially owned reflects the 10-for-1 Share Consolidation undertaken by the Issuer, effective October 1, 2024. Pursuant to the Share Consolidation, the 98,360,094 Ordinary Shares previously reported as beneficially owned by the Reporting Persons were consolidated into 9,836,010 Ordinary Shares. The percentage of beneficial ownership is based on 41,212,693 Ordinary Shares issued and outstanding as of July 11, 2025, which figure is provided by the Issuer to the Reporting Persons.
(b)	Each of the Reporting Persons has shared power to vote or to direct the vote of, and shared power to dispose or to direct the disposition of, the 9,836,010 Ordinary Shares reported herein.
(c)	None of the Reporting Persons has effected any transaction during the past 60 days in any Ordinary Shares.
(d)	Not applicable.
(e)	Not applicable.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 99.1 Joint Filing Agreement, dated July 15, 2025, among the Reporting Persons.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Fung Ching Wong

Signature:	/s/ Fung Ching Wong
Name/Title:	Fung Ching Wong
Date:	07/15/2025

Apex Prospect Limited

Signature:	/s/ Fung Ching Wong
Name/Title:	Fung Ching Wong, Director
Date:	07/15/2025